Key in-en exclusion criteria NX-5948-301

- Patients must be ≥ 18 years of age.
- Patients in Phase 1a (Dose Escalation) must have histologically confirmed R/R CLL, SLL, DLBCL, including transformed indolent lymphoma, Richter-transformed DLBCL, high-grade B-cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangements, high-grade B-cell lymphomas NOS), FL (grade 1–3a; eligibility for systemic treatment as determined by the GELF criteria), MCL, MZL (EMZL, MALT, NMZL, SMZL), or WM, including those with secondary CNS involvement in any disease indication listed or PCNSL
- Received at least 2 prior lines of therapy and have no other therapies known to provide clinical benefit. PCNSL after at least 1 prior therapy.
- Patients must have radiographically measurable disease per response criteria specific to the malignancy (ie, International Workshop on CLL [iwCLL], Lugano Classification of Lymphoma response criteria, WM response criteria, or International PCNSL Collaboration Group criteria) by computed tomography (CT), CT/positron emission tomography (PET) scan, or magnetic resonance imaging (MRI). Target lymph nodes must be > 1.5 cm and extranodal lesions must be ≥ 1.0 cm in longest diameter.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (0-2 for patients with PCNSL or secondary CNS involvement)
- Adequate organ and bone marrow function, in the absence of growth factors and without platelet transfusions, as defined by laboratory parameters.

Key exclusion criteria: zie “advertentietekst”